Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etonogestrel + levonorgestrel is a hypothetical combination of two synthetic progestogens, both widely used in hormonal contraception. Etonogestrel is a third-generation progestogen found in contraceptive implants (such as Nexplanon) and vaginal rings, while levonorgestrel is used in various forms including oral pills, intrauterine devices (IUDs), and emergency contraception. Both agents primarily act by inhibiting ovulation, thickening cervical mucus to prevent sperm penetration, and altering the endometrial lining to reduce the likelihood of implantation. Etonogestrel has weaker androgenic properties compared to levonorgestrel[6][7]. Levonorgestrel can also be used for emergency contraception within 5 days after unprotected intercourse[3][7]. There are currently no marketed products or clinical evidence supporting the use of these two agents together in a single formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etonogestrel + levonorgestrel.